Literature DB >> 28165915

Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples.

Yi-Fan Zhang1, Mitchell Ho1.   

Abstract

Rabbit monoclonal antibodies (RabMAbs) can recognize diverse epitopes, including those poorly immunogenic in mice and humans. However, there have been only a few reports on RabMAb humanization, an important antibody engineering step usually done before clinical applications are investigated. To pursue a general method for humanization of RabMAbs, we analyzed the complex structures of 5 RabMAbs with their antigens currently available in the Protein Data Bank, and identified antigen-contacting residues on the rabbit Fv within the 6 Angstrom distance to its antigen. We also analyzed the supporting residues for antigen-contacting residues on the same heavy or light chain. We identified "HV4" and "LV4" in rabbit Fvs, non-complementarity-determining region (CDR) loops that are structurally close to the antigen and located in framework 3 of the heavy chain and light chain, respectively. Based on our structural and sequence analysis, we designed a humanization strategy by grafting the combined Kabat/IMGT/Paratome CDRs, which cover most antigen-contacting residues, into a human germline framework sequence. Using this strategy, we humanized 4 RabMAbs that recognize poorly immunogenic epitopes in the cancer target mesothelin. Three of the 4 humanized rabbit Fvs have similar or improved functional binding affinity for mesothelin-expressing cells. Interestingly, 4 immunotoxins composed of the humanized scFvs fused to a clinically used fragment of Pseudomonas exotoxin (PE38) showed stronger cytotoxicity against tumor cells than the immunotoxins derived from their original rabbit scFvs. Our data suggest that grafting the combined Kabat/IMGT/Paratome CDRs to a stable human germline framework can be a general approach to humanize RabMAbs.

Entities:  

Keywords:  Humanization; mesothelin; paratope; rabbit monoclonal antibody; recombinant immunotoxin; structure alignment

Mesh:

Substances:

Year:  2017        PMID: 28165915      PMCID: PMC5384799          DOI: 10.1080/19420862.2017.1289302

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  46 in total

1.  Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method.

Authors:  Lourdes Roque-Navarro; Cristina Mateo; Josefa Lombardero; Geraudis Mustelier; Alicia Fernández; Katya Sosa; Sherrie L Morrison; Rolando Pérez
Journal:  Hybrid Hybridomics       Date:  2003-08

2.  Molecular basis of the allelic inheritance of rabbit immunoglobulin VH allotypes: implications for the generation of antibody diversity.

Authors:  K L Knight; R S Becker
Journal:  Cell       Date:  1990-03-23       Impact factor: 41.582

3.  Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

Authors:  C Jackisch; S-B Kim; V Semiglazov; B Melichar; X Pivot; C Hillenbach; D Stroyakovskiy; B L Lum; R Elliott; H A Weber; G Ismael
Journal:  Ann Oncol       Date:  2014-11-17       Impact factor: 32.976

4.  A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.

Authors:  Jaafar N Haidar; Qing-An Yuan; Lin Zeng; Mark Snavely; Xenia Luna; Haifan Zhang; Wei Zhu; Dale L Ludwig; Zhenping Zhu
Journal:  Proteins       Date:  2011-12-16

5.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

6.  Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev.

Authors:  Stephen J Stahl; Norman R Watts; Christoph Rader; Michael A DiMattia; Rose G Mage; Ira Palmer; Joshua D Kaufman; Jonathan M Grimes; David I Stuart; Alasdair C Steven; Paul T Wingfield
Journal:  J Mol Biol       Date:  2010-02-04       Impact factor: 5.469

7.  Deimmunization of monoclonal antibodies.

Authors:  Tim D Jones; Laura J Crompton; Frank J Carr; Matthew P Baker
Journal:  Methods Mol Biol       Date:  2009

8.  Structural consensus among antibodies defines the antigen binding site.

Authors:  Vered Kunik; Bjoern Peters; Yanay Ofran
Journal:  PLoS Comput Biol       Date:  2012-02-23       Impact factor: 4.475

9.  I-TASSER server for protein 3D structure prediction.

Authors:  Yang Zhang
Journal:  BMC Bioinformatics       Date:  2008-01-23       Impact factor: 3.169

10.  Systematic characterization and comparative analysis of the rabbit immunoglobulin repertoire.

Authors:  Jason J Lavinder; Kam Hon Hoi; Sai T Reddy; Yariv Wine; George Georgiou
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more
  19 in total

1.  Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display.

Authors:  Ruonan Feng; Ruixue Wang; Jessica Hong; Christopher M Dower; Brad St Croix; Mitchell Ho
Journal:  Antib Ther       Date:  2020-02-17

2.  Protodomains: Symmetry-Related Supersecondary Structures in Proteins and Self-Complementarity.

Authors:  Philippe Youkharibache
Journal:  Methods Mol Biol       Date:  2019

3.  Human endotrophin as a driver of malignant tumor growth.

Authors:  Dawei Bu; Clair Crewe; Christine M Kusminski; Ruth Gordillo; Alexandra L Ghaben; Min Kim; Jiyoung Park; Hui Deng; Wei Xiong; Xiao-Zheng Liu; Per Eystein Lønning; Nils Halberg; Adan Rios; Yujun Chang; Anneliese Gonzalez; Ningyan Zhang; Zhiqiang An; Philipp E Scherer
Journal:  JCI Insight       Date:  2019-03-21

4.  Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Authors:  Jared L Spidel; Earl F Albone; Xin Cheng; Benjamin Vaessen; Sara Jacob; Andrew Z Milinichik; Arielle Verdi; J Bradford Kline; Luigi Grasso
Journal:  MAbs       Date:  2017-05-25       Impact factor: 5.857

5.  Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development.

Authors:  Xun Gui; Mi Deng; Hao Song; Yuanzhi Chen; Jingjing Xie; Zunling Li; Licai He; Fangfang Huang; Yixiang Xu; Yasuaki Anami; Hai Yu; Chenyi Yu; Leike Li; Zihao Yuan; Xiaoying Xu; Qihui Wang; Yan Chai; Tao Huang; Yi Shi; Kyoji Tsuchikama; X Charlene Liao; Ningshao Xia; George F Gao; Ningyan Zhang; Cheng Cheng Zhang; Zhiqiang An
Journal:  Cancer Immunol Res       Date:  2019-06-18       Impact factor: 11.151

6.  Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.

Authors:  Earl F Albone; Jared L Spidel; Xin Cheng; Young Chul Park; Sara Jacob; Andrew Z Milinichik; Ben Vaessen; Janet Butler; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2017-04-10       Impact factor: 4.742

7.  Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.

Authors:  Sakshi Tomar; Jingli Zhang; Manakamana Khanal; Jessica Hong; Abhilash Venugopalan; Qun Jiang; Manjistha Sengupta; Markku Miettinen; Nan Li; Ira Pastan; Mitchell Ho; Raffit Hassan
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

8.  Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications.

Authors:  Rebecca S Goydel; Justus Weber; Haiyong Peng; Junpeng Qi; Jo Soden; Jim Freeth; HaJeung Park; Christoph Rader
Journal:  J Biol Chem       Date:  2020-03-19       Impact factor: 5.157

9.  Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells.

Authors:  Liu Yang; Xin Chen; Qian Wang; Yuankui Zhu; Changfa Wu; Xuqian Ma; Dianbao Zuo; Huixia He; Le Huang; Jingwen Li; Chunjiao Xia; Sheng Hu; Xiaoqing Yang; Mingqian Feng
Journal:  Oncol Lett       Date:  2021-05-20       Impact factor: 2.967

10.  Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.

Authors:  Bryan D Fleming; Daniel J Urban; Matthew D Hall; Thomas Longerich; Tim F Greten; Ira Pastan; Mitchell Ho
Journal:  Hepatology       Date:  2020-01-27       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.